Small molecule inhibitors of phospholipase C from a novel high-throughput screen

Journal of Biological Chemistry

Volumn 288, Issue 8, 2013, Pages 5840-5848

  Huang, Weigang ^a   Barrett, Matthew ^b   Hajicek, Nicole ^b   Hicks, Stephanie ^b   Harden, T Kendall ^b   Sondek, John ^b   Zhang, Qisheng ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH-THROUGHPUT SCREENS; PHOSPHOLIPASE C; SMALL MOLECULE INHIBITOR; SMALL MOLECULES; THERAPEUTIC TARGETS;

MOLECULES;

FLUORESCENT SCREENS;

ADENOSINE TRIPHOSPHATE; AURINTRICARBOXYLIC ACID; G PROTEIN COUPLED RECEPTOR; ISOENZYME; PHOSPHOLIPASE C; PHOSPHOLIPASE C BETA3; PHOSPHOLIPASE C DELTA1; PHOSPHOLIPASE C GAMMA1; PHOSPHOLIPASE C INHIBITOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; ENZYME REGULATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL ASSAY; CHEMISTRY, PHARMACEUTICAL; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; MODELS, CHEMICAL; PHOSPHOLIPASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY; TYPE C PHOSPHOLIPASES;

EID: 84874336095     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.422501     Document Type: Article

References (53)

1. Harden, T. K., and Sondek, J. (2006) Regulation of phospholipase C isozymes by Ras superfamily GTPases. Annu. Rev. Pharmacol. Toxicol. 46, 355-379
2. Sala, G., Dituri, F., Raimondi, C., Previdi, S., Maffucci, T., Mazzoletti, M., Rossi, C., Iezzi, M., Lattanzio, R., Piantelli, M., Iacobelli, S., Broggini, M., and Falasca, M. (2008) Phospholipase C+1 is required for metastasis development and progression. Cancer Res. 68, 10187-10196
3. Shepard, C. R., Kassis, J., Whaley, D. L., Kim, H. G., and Wells, A. (2007) PLC+ contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26, 3020-3026
4. Bertagnolo, V., Benedusi, M., Brugnoli, F., Lanuti, P., Marchisio, M., Querzoli, P., and Capitani, S. (2007) Phospholipase C+2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis 28, 1638-1645
5. Zhang, L., Malik, S., Kelley, G. G., Kapiloff, M. S., and Smrcka, A. V. (2011) Phospholipase C+ scaffolds to muscle-specific A kinase anchoring protein (mAKAP+) and integrates multiple hypertrophic stimuli in cardiac myocytes. J. Biol. Chem. 286, 23012-23021
6. Woodcock, E. A., Grubb, D. R., and Iliades, P. (2010) Potential treatment of cardiac hypertrophy and heart failure by inhibiting the sarcolemmal binding of phospholipase C+1b. Curr. Drug Targets 11, 1032-1040
7. Kurian, M. A., Meyer, E., Vassallo, G., Morgan, N. V., Prakash, N., Pasha, S., Hai, N. A., Shuib, S., Rahman, F., Wassmer, E., Cross, J. H., O'Callaghan, F. J., Osborne, J. P., Scheffer, I. E., Gissen, P., and Maher, E. R. (2010) Phospholipase C+1 deficiency is associated with early-onset epileptic encephalopathy. Brain 133, 2964-2970
8. Bleasdale, J. E., Thakur, N. R., Gremban, R. S., Bundy, G. L., Fitzpatrick, F. A., Smith, R. J., and Bunting, S. (1990) Selective inhibition of receptorcoupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther. 255, 756-768
9. Bala, G. A., Thakur, N. R., and Bleasdale, J. E. (1990) Characterization of the major phosphoinositide-specific phospholipase C of human amnion. Biol. Reprod. 43, 704-711
10. Hollywood, M. A., Sergeant, G. P., Thornbury, K. D., and McHale, N. G. (2010) The PI-PLC inhibitor U-73122 is a potent inhibitor of the SERCA pump in smooth muscle. Br. J. Pharmacol. 160, 1293-1294
11. Pulcinelli, F. M., Gresele, P., Bonuglia, M., and Gazzaniga, P. P. (1998) Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. Biochem. Pharmacol. 56, 1481-1484
12. Berven, L. A., and Barritt, G. J. (1995) Evidence obtained using single hepatocytes for inhibition by the phospholipase C inhibitor U73122 of store-operated Ca2+ inflow. Biochem. Pharmacol. 49, 1373-1379
13. Wang, J. P. (1996) U-73122, an aminosteroid phospholipase C inhibitor, may also block Ca2+ influx through phospholipase C-independent mechanism in neutrophil activation. Naunyn-Schmiedebergs Arch. Pharmacol. 353, 599-605
14. Wilsher, N. E., Court, W. J., Ruddle, R., Newbatt, Y. M., Aherne, W., Sheldrake, P. W., Jones, N. P., Katan, M., Eccles, S. A., and Raynaud, F. I. (2007) The phosphoinositide-specific phospholipase C inhibitor U73122 (1-(6-((17 β-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1Hpyrrole-2,5-dione) spontaneously forms conjugates with common components of cell culture medium. Drug Metab. Dispos. 35, 1017-1022
15. Burgdorf, C., Schäfer, U., Richardt, G., and Kurz, T. (2010) U73122, an aminosteroid phospholipase C inhibitor, is a potent inhibitor of cardiac phospholipaseDby a PIP2-dependent mechanism. J. Cardiovasc. Pharmacol. 55, 555-559
16. Feisst, C., Albert, D., Steinhilber, D., and Werz, O. (2005) The aminosteroid phospholipase C antagonist U-73122 (1-[6-[[17-β-3- methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) potently inhibits human 5-lipoxygenase in vivo and in vitro. Mol. Pharmacol. 67, 1751-1757
17. Vickers, J. D. (1993) U73122 affects the equilibria between the phosphoinositides as well as phospholipase C activity in unstimulated and thrombin-stimulated human and rabbit platelets. J. Pharmacol. Exp. Ther. 266, 1156-1163
18. Klein, R. R., Bourdon, D. M., Costales, C. L., Wagner, C. D., White, W. L., Williams, J. D., Hicks, S. N., Sondek, J., and Thakker, D. R. (2011) Direct activation of human phospholipase C by its well known inhibitor U73122. J. Biol. Chem. 286, 12407-12416
19. Zaikova, T. O., Rukavishnikov, A. V., Birrell, G. B., Griffith, O. H., and Keana, J. F. (2001) Synthesis of fluorogenic substrates for continuous assay of phosphatidylinositol-specific phospholipase C. Bioconjug. Chem. 12, 307-313
20. Scholze, H., Stütz, H., Paltauf, F., and Hermetter, A. (1999) Fluorescent inhibitors for the qualitative and quantitative analysis of lipolytic enzymes. Anal. Biochem. 276, 72-80
21. Hendrickson, E. K., Johnson, J. L., and Hendrickson, H. S. (1991) A fluorescent substrate for the assay of phosphatidylinositol-specific phospholipase C: 4-(1-pyreno)butylphosphoryl-1-myo-inositol. Bioorg. Med. Chem. Lett. 1, 619-662
22. Rukavishnikov, A. V., Smith, M. P., Birrell, G. B., Keana, J. F., and Griffith, O. H. (1998) Synthesis of a new fluorogenic substrate for the assay of phosphoinositide-specific phospholipase C. Tetrahedron Lett. 39, 6637-6640
23. Shashidhar, M. S., Volwerk, J. J., Keana, J. F., and Griffith, O. H. (1991) A fluorescent substrate for the continuous assay of phosphatidylinositolspecific phospholipase C: synthesis and application of 2-naphthyl-myoinositol 1-phosphate. Anal. Biochem. 198, 10-14
24. Heinz, D. W., Essen, L. O., and Williams, R. L. (1998) Structural and mechanistic comparison of prokaryotic and eukaryotic phosphoinositidespecific phospholipases C. J. Mol. Biol. 275, 635-650
25. Rose, T. M., and Prestwich, G. D. (2006) Synthesis and evaluation of fluorogenic substrates for phospholipase D and phospholipase C. Org. Lett. 8, 2575-2578
26. Rukavishnikov, A. V., Zaikova, T. O., Birrell, G. B., Keana, J. F., and Griffith, O. H. (1999) Synthesis of a new fluorogenic substrate for the continuous assay of mammalian phosphoinositide-specific phospholipase C. Bioorg. Med. Chem. Lett. 9, 1133-1136
27. Rebecchi, M. J., Eberhardt, R., Delaney, T., Ali, S., and Bittman, R. (1993) Hydrolysis of short acyl chain inositol lipids by phospholipase C+1. J. Biol. Chem. 268, 1735-1741
28. Liu, Y., Mihai, C., Kubiak, R. J., Rebecchi, M., and Bruzik, K. S. (2007) Phosphorothiolate analogues of phosphatidylinositols as assay substrates for phospholipase C. ChemBioChem 8, 1430-1439
29. Huang, W., Hicks, S. N., Sondek, J., and Zhang, Q. (2011) A fluorogenic, small molecule reporter for mammalian phospholipase C isozymes. ACS Chem. Biol. 6, 223-228
30. Carter, R. L., Fricks, I. P., Barrett, M. O., Burianek, L. E., Zhou, Y., Ko, H., Das, A., Jacobson, K. A., Lazarowski, E. R., and Harden, T. K. (2009) Quantification ofGi-mediated inhibition of adenylyl cyclase activity reveals that UDPis a potent agonist of the human P2Y14 receptor. Mol. Pharmacol. 76, 1341-1348
31. Harden, T. K., Scheer, A. G., and Smith, M. M. (1982) Differential modification of the interaction of cardiac muscarinic cholinergic and betaadrenergic receptors with a guanine nucleotide binding component(s). Mol. Pharmacol. 21, 570-580
32. Salomon, Y., Londos, C., and Rodbell, M. (1974) A highly sensitive adenylate cyclase assay. Anal. Biochem. 58, 541-548
33. Feng, B. Y., and Shoichet, B. K. (2006) A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550-553
34. McGovern, S. L., Helfand, B. T., Feng, B., and Shoichet, B. K. (2003) A specific mechanism of nonspecific inhibition. J. Med. Chem. 46, 4265-4272
35. Feng, B. Y., Shelat, A., Doman, T. N., Guy, R. K., and Shoichet, B. K. (2005) High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 1, 146-148
36. Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., and Austin, C. P. (2007) A high-throughput screen for aggregationbased inhibition in a large compound library. J. Med. Chem. 50, 2385-2390
37. Hicks, S. N., Jezyk, M. R., Gershburg, S., Seifert, J. P., Harden, T. K., and Sondek, J. (2008) General and versatile autoinhibition of PLC isozymes. Mol. Cell 31, 383-394
38. Bourdon, D. M., Wing, M. R., Edwards, E. B., Sondek, J., and Harden, T. K. (2006) Quantification of isozyme-specific activation of phospholipaseC+2 by Rac GTPases and phospholipase C+ by Rho GTPases in an intact cell assay system. Methods Enzymol. 406, 489-499
39. Bembenek, M. E., Jain, S., Prack, A., Li, P., Chee, L., Cao, W., Spurling, H., Roy, R., Fish, S., Rokas, M., Parsons, T., and Meyers, R. (2003) Development of a high-throughput assay for two inositol-specific phospholipase Cs using a scintillation proximity format. Assay Drug Dev. Technol. 1, 435-443
40. Owens, M. R., and Holme, S. (1996) Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. Thrombosis Res. 81, 177-185
41. Gerber, A. N., Masuno, K., and Diamond, M. I. (2009) Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc. Natl. Acad. Sci. U.S.A. 106, 4929-4934
42. Heiduschka, P., and Thanos, S. (2000) Aurintricarboxylic acid promotes survival and regeneration of axotomised retinal ganglion cells in vivo. Neuropharmacology 39, 889-902
43. Benchokroun, Y., Couprie, J., and Larsen, A. K. (1995) Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochemical Pharmacol. 49, 305-313
44. Li, M., Shandilya, S. M., Carpenter, M. A., Rathore, A., Brown, W. L., Perkins, A. L., Harki, D. A., Solberg, J., Hook, D. J., Pandey, K. K., Parniak, M. A., Johnson, J. R., Krogan, N. J., Somasundaran, M., Ali, A., Schiffer, C. A., and Harris, R. S. (2012) First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 7, 506-517
45. Milanovic, M., Radtke, S., Peel, N., Howell, M., Carrière, V., Joffre, C., Kermorgant, S., and Parker, P. J. (2012) Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid. Int. J. Cancer 130, 1060-1070
46. Abnet, C. C., Freedman, N. D., Hu, N., Wang, Z., Yu, K., Shu, X. O., Yuan, J. M., Zheng, W., Dawsey, S. M., Dong, L. M., Lee, M. P., Ding, T., Qiao, Y. L., Gao, Y. T., Koh, W. P., Xiang, Y. B., Tang, Z. Z., Fan, J. H., Wang, C., Wheeler, W., Gail, M. H., Yeager, M., Yuenger, J., Hutchinson, A., Jacobs, K. B., Giffen, C. A., Burdett, L., Fraumeni, J. F., Jr., Tucker, M. A., Chow, W. H., Goldstein, A. M., Chanock, S. J., and Taylor, P. R. (2010) A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat. Genet. 42, 764-767
47. Lo Vasco, V. R., Calabrese, G., Manzoli, L., Palka, G., Spadano, A., Morizio, E., Guanciali-Franchi, P., Fantasia, D., and Cocco, L. (2004) Inositidespecific phospholipase C+1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18, 1122-1126
48. Li, M., Edamatsu, H., Kitazawa, R., Kitazawa, S., and Kataoka, T. (2009) Phospholipase C+ promotes intestinal tumorigenesis of ApcMin/+ mice through augmentation of inflammation and angiogenesis. Carcinogenesis 30, 1424-1432
49. Kassis, J., Moellinger, J., Lo, H., Greenberg, N. M., Kim, H. G., and Wells, A. (1999) A role for phospholipase C β-mediated signaling in tumor cell invasion. Clin. Cancer Res. 5, 2251-2260
50. Follo, M. Y., Finelli, C., Clissa, C., Mongiorgi, S., Bosi, C., Martinelli, G., Baccarani, M., Manzoli, L., Martelli, A. M., and Cocco, L. (2009) Phosphoinositide-phospholipase C+1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J. Clin. Oncol. 27, 782-790
51. Bai, Y., Edamatsu, H., Maeda, S., Saito, H., Suzuki, N., Satoh, T., and Kataoka, T. (2004) Crucial role of phospholipase C+ in chemical carcinogen-induced skin tumor development. Cancer Res. 64, 8808-8810
52. Wang, Z., Liu, B., Wang, P., Dong, X., Fernandez-Hernando, C., Li, Z., Hla, T., Li, Z., Claffey, K., Smith, J. D., and Wu, D. (2008) Phospholipase C+3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. J. Clin. Invest. 118, 195-204
53. McOmish, C. E., Burrows, E. L., Howard, M., and Hannan, A. J. (2008) PLC+1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. Hippocampus 18, 824-834